>> LIVE FROM NEW YORK, I AM SCARLET FU. >> I AM TIM STENOVEC. WELCOME TO "BLOOMBERG CRYPTO." >> HERE IS WHAT IS AT STAKE TODAY.BITCOIN IS SEEING A CRYPTO WINTER. IT CONTINUES TO SELLOFF TO START 2026. TIM: WE WILL SPEAK ABOUT THIS VOLATILITY AND RECENT EARNINGS.MIKE NOVOGRATZ IS JOINING US, FOUNDER AND CEO OF GALAXY DIGITAL. WE WILL SPEAK WITH SUMMER MERSINGER, CEO OF THE BLOCKCHAIN ASSOCIATION AND FORMER COMMISSIONER AT THE CFTC. SHE WAS IN THE ROOM FOR MONDAY'S BIG WHITE HOUSE MEETING IS ALL SIDES LOOK TO ...

Core Viewpoint - Novo Nordisk's stock is experiencing a decline following the release of its 2026 sales and operating profit outlook, which indicates challenges in growth due to pricing pressures and competition in the market [1]. Group 1: 2026 Outlook - Novo Nordisk anticipates a reported sales and operating profit boost in 2026 from a $4.2 billion reversal of the 340B Drug Pricing Program in the U.S., with a $400 million exclusion in 2025 [2]. - Excluding this one-time item, the mid-point growth guidance for 2026 indicates a sales decline of -1% and an operating profit increase of 11% at constant exchange rates (CER) [2]. - Adjusted sales growth for 2026, excluding the 340B reversal, is projected to be between -5% and -13% at CER [2]. Group 2: Factors Impacting Sales Outlook - The sales outlook is negatively affected by lower realized prices, the "Most Favoured Nations" agreement in the U.S., patent expirations of semaglutide in certain markets, and increased competition [3]. - The CEO highlighted that Novo Nordisk will encounter pricing challenges in a more competitive environment in 2026 [3]. Group 3: U.S. Market Conditions - Current assumptions for the U.S. market reflect ongoing GLP-1 prescription trends, heightened competition, reduced Medicaid coverage for obesity drugs, and pricing pressures linked to the MFN agreement [4]. Group 4: 2025 Performance - In 2025, Novo Nordisk's sales rose by 10% to DKK 309.06 billion at CER, while operating profit increased by 6% to DKK 127.66 billion, falling short of earlier guidance [5]. - Net profit saw a slight increase to DKK 102.43 billion, with earnings per share reported at DKK 23.03 [5]. - U.S. sales were positively influenced by gross-to-net sales adjustments [5]. Group 5: Product Launch and Market Response - The Wegovy pill was launched on January 5, 2026, with total weekly prescriptions reaching approximately 50,000 by January 23, primarily driven by the 1.5 mg starter dose in the self-pay channel [6]. - As of the publication date, Novo Nordisk's stock price had decreased by 14.02% to $50.62 [6].

The maker of Ozempic and Wegovy blamed pricing pressures and competition for its downbeat outlook. ...

Novo Nordisk stock (NVO) plunged approximately 15% after the Danish pharmaceutical giant posted better-than-expected 2025 results but delivered a weak 2026 outlook. The company reported full-year 2025... ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Financial Performance - In 2025, Novo Nordisk served over 45.6 million people with serious chronic diseases, achieving global sales growth of 10.3% and operating profit growth of 6.0% at constant exchange rates[8]. - Reported sales growth for 2023 was 31.3%, with a constant exchange rate growth of 35.6%[100]. - Operating profit growth for 2023 was reported at 37.1%, with a constant exchange rate growth of 43.7%[100]. - Sales growth is projected to decline to 6.4% by 2025, with operating profit growth expected to be (0.5%) in the same year[100]. - Future sales growth in constant exchange rates is forecasted at 10.3% for 2025[100]. Executive Remuneration - The total Board remuneration for 2025 amounted to DKK 23.8 million, reflecting a 3% increase from DKK 23.0 million in 2024[21]. - Total executive remuneration in 2025 amounted to DKK 193.3 million, a 38% decrease from DKK 311.1 million in 2024, primarily due to lower performance on incentive programs[37]. - The total remuneration for CEO Maziar Mike Doustdar in 2025 was DKK 20.7 million, down 39% from DKK 57.1 million in 2024, with 47% being fixed and 53% variable[38]. - The total remuneration for Lars Fruergaard Jørgensen during his tenure as CEO in 2025 was DKK 22.2 million, with severance payments totaling DKK 42.9 million[42]. - The total remuneration for the CEO, CFO, and former CEO reflects a strategic shift in compensation policies, with a focus on aligning incentives with company performance[94]. Incentive Programs - The short-term incentive for Maziar Mike Doustdar in 2025 was set at 24.7% of the maximum incentive, equivalent to 2.96 months' base salary[14]. - The short-term incentive program (STIP) for 2025 resulted in a payout of 18.8% of the maximum for group performance, with the CEO receiving 24.7% and the CFO receiving 24.4% of their maximum potential[45]. - The long-term incentive programme for 2023 achieved 92% of the maximum allocation, while performance for LTIP 2024 and LTIP 2025 is tracking below targets due to reduced financial performance[14]. - The long-term incentive program for 2025 is share-based with a three-year performance period, tracking below targets after the first year due to challenges faced[41]. - The average annual sales growth performance for the LTIP 2023-2025 was 24%, resulting in a maximum payout of 33%[72]. Board Governance - The Board of Directors reduced its size from 12 to 9 members following the Extraordinary General Meeting in November 2025[20]. - The remuneration policy for the Board of Directors was benchmarked against Nordic general industry and European pharma companies, with the Chair's fees above the upper quartile[29]. - The Remuneration Committee will not propose changes to the Remuneration Policy for adoption at the Annual General Meeting in March 2026[16]. - The Board's assessment of executive remuneration considers market benchmarks and the balance between fixed and variable pay[44]. - The company plans to present the Remuneration Report for an advisory vote at the Annual General Meeting in 2026[106]. Environmental Impact - Novo Nordisk's CO2e emissions increased by 19% in 2025 compared to 2024, primarily due to construction and expansion activities[9]. - The portion of expensed total remuneration linked to climate-related performance in 2025 is 1%[88]. Shareholder Information - The total shareholdings of Board members at the end of 2025 amounted to 588,712 shares, with a market value of DKK 191.6 million[35]. - As of December 31, 2025, executives held a total of 784,263 shares, with a market value of DKK 255.1 million[85]. - The share price decreased by 32.4% during the performance period (2023-2025), aligning the interests of shareholders and executives[73]. - The share price development from the grant in February 2023 to the end of 2025 shows a decline from DKK 481.00 to DKK 325.25, reflecting a negative performance adjustment[77]. Employee Remuneration - The average annual employee remuneration excluding registered executives in the parent company increased from DKK 0.85 million in 2021 to DKK 1.12 million in 2025, reflecting a growth of 31.8% over the five-year period[99]. - The average remuneration growth for the parent company was 1.8% in 2021, 4.4% in 2022, 8.6% in 2023, 5.2% in 2024, and projected at 10.1% in 2025[99]. - The average employee remuneration excluding registered executives in the group increased from DKK 0.79 million in 2021 to DKK 1.01 million in 2025[99]. - The CEO/Employee ratio for the group was 74 in 2021 and is projected to be 37 in 2025, reflecting a significant change in the compensation structure[99].

Danish drug maker Novo Nordisk said on Wednesday it had appointed Jamey Millar head of its U.S. business, and Hong Chow head of product and portfolio strategy. ...

The Danish drugmaker said adjusted sales should decline between 5% and 13% at constant exchange rates in 2026, a reversal from last year, when sales grew 10%. https://t.co/HP6jn6TMbw ...

The Danish drugmaker said adjusted sales should decline between 5% and 13% at constant exchange rates in 2026, a reversal from last year, when sales grew 10%. ...

Novo Nordisk's U.S. shares plummeted late Tuesday after the company said it sees sales and profit growth declining this year, expecting a sales hit.The company published the forecast as it reported full-year 2025 sales, ahead of the quarterly report expected Wednesday morning. Novo's American depositary shares fell 11% as of 12:05 pm ET. The results were published after the closing bell in Copenhagen, where the company has its primary listing.Its forecast comes as the Danish drugmaker is fighting to regain ...